Study of PAS-004 for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This phase 1 trial tests an oral drug called PAS-004 for people with advanced solid tumors that have certain gene changes. It aims to find a safe dose and see if the drug can stop tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and able to swallow pills.
- Your advanced cancer must have a change in the RAS, NF1, or RAF gene (confirmed by a tumor biopsy if needed).
- You must have tried standard treatments already or not be able to take them.
- You need to be in fairly good health (ECOG score 0 or 1) with adequate organ function.
- You must agree to use effective birth control during the study and for 90 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new oral medication (AN9025) for people with advanced solid tumors that have a RAS mutation, such as pancreatic, colorectal, lung, or melanoma. It aims to see if the drug can shrink tumors or slow their growth when other treatments have stopped working.
This trial tests an oral medication called PAS-004 for adults with Neurofibromatosis Type 1 who have at least one symptomatic plexiform neurofibroma that cannot be surgically removed. The goal is to see if the drug can shrink these tumors or improve symptoms, and to understand side effects.
This trial tests a new drug, BPI-572270, for people with advanced solid tumors that have specific changes in the RAS gene. It may be an option if you have already tried standard treatments for your cancer type.
This study tests an experimental drug called VVD-159642 in people with advanced solid tumors that have specific genetic changes (RAS or EGFR alterations, or HER2 overexpression). The goal is to see if the drug is safe and tolerable.
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
This trial tests an experimental oral drug called ERAS-0015 for people with advanced solid tumors that have certain genetic changes (RAS mutations). It may be an option if you have no standard treatments left or cannot take them.
Hear when a new RAS Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.